Edition:
United Kingdom

Biotechnology & Medical Research

Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

Sept 19 (Reuters) - Cytokinetics Inc :Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure.Cytokinetics - ‍pharmacokinetics, pharmacodynamics, safety, tolerability data from trial were consistent with...

12:30pm BST

Abivax says first patient dosed in phase 2a ABX464 study

Sept 18 (Reuters) - ABIVAX SA ::ABIVAX: FIRST PATIENT DOSED IN THREE-MONTH COHORT OF PHASE 2A STUDY OF ORAL ABX464 IN HIV-SUPPRESSED PATIENTS.INITIAL RESULTS OF FIRST COHORT ARE EXPECTED IN FIRST WEEK OF OCTOBER.INITIAL RESULTS OF SECOND COHORT ARE EXPECTED IN Q2 OF 2018..

Monday, 18 Sep 2017

Innate Pharma H1 operating loss widens to 18.2 million euros

Sept 18 (Reuters) - INNATE PHARMA SA ::‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS(1) FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​.‍A NET LOSS FOR FIRST HALF OF 2017 AMOUNTING TO EUR 23.4M (EUR 3.2M FOR FIRST HALF OF 2016).​.H1 REVENUE EUR 21.3 MILLION VERSUS EUR 20.7...

Monday, 18 Sep 2017

Medlab Clinical says anti-depression product granted a 20 year Australia patent

Sept 18 (Reuters) - Medlab Clinical Ltd :Granted a 20 year patent covering the australian market for its probiotic product, NRGBiotic.

Monday, 18 Sep 2017

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.